SEC Comment Letter 0000000000-24-001224 to Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc.
Date: Jan. 31, 2024 · CIK: 0001796280 · Accession: 0000000000-24-001224
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276719
Letter
United States securities and exchange commission logo January 31, 2024 Jacob M. Chacko, M.D. President and Chief Executive Officer Oric Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 Re:Oric Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 26, 2024 File No. 333-276719 Dear Jacob M. Chacko: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Knapp, Esq.
Show Raw Text
United States securities and exchange commission logo
January 31, 2024
Jacob M. Chacko, M.D.
President and Chief Executive Officer
Oric Pharmaceuticals, Inc.
240 E. Grand Ave, 2nd Floor
South San Francisco, California 94080
Re:Oric Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed January 26, 2024
File No. 333-276719
Dear Jacob M. Chacko:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jennifer Knapp, Esq.